Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Geert R. Kersten Esq. | Chief Executive & Financial Officer, Treasurer and Director | 709.72k | -- | 1959 |
| Ms. Patricia B. Prichep | Chief Financial & Operations Officer, Compliance Officer & Corporate Secretary | 298.23k | -- | 1951 |
| Dr. Eyal Talor Ph.D. | Chief Scientific Officer | 355.64k | -- | 1956 |
| Dr. Daniel H. Zimmerman Ph.D. | Senior Vice President of Research & Cellular Immunology | -- | -- | 1941 |
| Mr. John Cipriano | Senior Vice President of Regulatory Affairs | 249.59k | -- | 1942 |
| Dr. Giovanni Selvaggi M.D. | Acting Chief Medical Officer | -- | -- | -- |
CEL-SCI Corporation
- Sector:
- Healthcare
- Industry: Biotechnology
Description
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Corporate Governance
Upcoming Events
May 13, 2025 at 8:00 PM UTC - May 19, 2025 at 8:00 PM UTC
CEL-SCI Corporation Earnings Date
Recent Events
March 3, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
November 5, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission